Lifesaving liver disease medicines
Versantis develops a new generation of liver disease therapeutics and diagnostics.
We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.
A life-saving therapy
Versantis’ lead product candidate, VS-01, is the first treatment for acute-on-chronic liver failure (ACLF), a life-threatening condition of high unmet medical need. The mortality of ACLF patients is alarming due to multi-organ failures resulting in dangerous accumulations of toxins in the blood. The versatile mechanism of action of VS-01 can simultaneously support the affected organs (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.
Versantis at the Investor Summit 2017, watch the video!
New publication in Advanced Functional Materials.
Versantis wins the MassChallenge!
Versantis in the Top10 of the best Swiss Biotech Startups.
Versantis wins a Cydan scholarship!
Japanese patent granted!